COMBINATION THERAPY IN STAGE-C AND STAGE-D PROSTATIC-CANCER - RATIONALE AND 5-YEAR CLINICAL-EXPERIENCE

被引：2
|
作者：
LABRIE, F
DUPONT, A
BELANGER, A
CUSAN, L
GIGUERE, M
LACOURCIERE, Y
LUTHY, I
BEGIN, D
LABRIE, C
SIMARD, J
MONFETTE, G
EMOND, J
机构：
[1] UNIV LAVAL, MED CTR, DEPT MED, QUEBEC CITY G1V 4G2, QUEBEC, CANADA
[2] UNIV LAVAL, MED CTR, DEPT NUCL MED, QUEBEC CITY G1V 4G2, QUEBEC, CANADA
[3] HOTEL DIEU, DEPT UROL, ST JEROME, QUEBEC, CANADA
[4] HOTEL DIEU, DEPT UROL, LEVIS, QUEBEC, CANADA
来源：
CANCER AND METASTASIS REVIEWS | 1987年 / 6卷 / 04期
关键词：
D O I：
10.1007/BF00047470
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：615 / 636
页数：22
相关论文
共 50 条
  • [41] 5-Year Lung Cancer Screening Experience Growth Curves of 18 Lung Cancers Compared to Histologic Type, CT Attenuation, Stage, Survival, and Size
    Lindell, Rebecca M.
    Hartman, Thomas E.
    Swensen, Stephen J.
    Jet, James R.
    Midthun, David E.
    Mandrekar, Jayawant N.
    CHEST, 2009, 136 (06) : 1586 - 1595
  • [42] Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer
    Zelefsky, MJ
    Wallner, KE
    Ling, CC
    Raben, A
    Hollister, T
    Wolfe, T
    Grann, A
    Gaudin, P
    Fuks, Z
    Leibel, SA
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) : 517 - 522
  • [43] The impact of the UK Government 'two week rule' (TWR) on lung cancer stage and 5-year survival - a decade of experience from the Royal Marsden Hospital (RMH)
    Dolly, S. O.
    Brandao, M.
    Taylor, C.
    Gunapala, R.
    Myerson, J.
    Waddell, T.
    Popat, S.
    Bhosle, J.
    O'Brien, M.
    LUNG CANCER, 2018, 115 : S18 - S18
  • [44] Effect of the intensiveness of inductive therapy on the response and on 5-year survival in patients with advanced (stage III) breast cancer receiving neo-adjuvant CMFVp chemotherapy
    Piechocki, J
    Pienkowski, T
    Dziewulska, E
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S72 - S72
  • [45] Differential impacts of clinical variables and 5-fluorouracil-based adjuvant chemotherapy on 5-year disease-free survival of patients with stage IIa and IIb colon cancer
    Kuo, Yi-Hung
    Huang, Cheng-Yi
    Chin, Chih-Chien
    Chen, Chih-Jung
    Huang, Wen-Shih
    You, Jeng-Fu
    Huang, Yun-Ching
    FORMOSAN JOURNAL OF SURGERY, 2018, 51 (02) : 41 - 49
  • [46] Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen alone or in combination) trial
    R Mansel
    G Locker
    L Fallowfield
    Á Benedict
    D Jones
    British Journal of Cancer, 2007, 97 : 152 - 161
  • [47] Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial
    Mansel, R.
    Locker, G.
    Fallowfield, L.
    Benedict, A.
    Jones, D.
    BRITISH JOURNAL OF CANCER, 2007, 97 (02) : 152 - 161
  • [48] Bevacizumab in Stage II-III Colon Cancer: 5-Year Update of the National Surgical Adjuvant Breast and Bowel Project C-08 Trial
    Allegra, Carmen J.
    Yothers, Greg
    O'Connell, Michael J.
    Sharif, Saima
    Petrelli, Nicholas J.
    Lopa, Samia H.
    Wolmark, Norman
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (03) : 359 - 364
  • [49] COMBINATION THERAPY WITH FLUTAMIDE AND CASTRATION (LHRH AGONIST OR ORCHIECTOMY) IN PREVIOUSLY UNTREATED PATIENTS WITH CLINICAL STAGE D2 PROSTATE-CANCER - TODAYS THERAPY OF CHOICE
    LABRIE, F
    DUPONT, A
    CUSAN, L
    GIGUERE, M
    BERGERON, N
    BORSANYI, JP
    LACOURCIERE, Y
    BELANGER, A
    EMOND, J
    MONFETTE, G
    BOUCHER, H
    LACHANCE, R
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1988, 30 (1-6): : 107 - 117
  • [50] Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: Overall survival and updated 5-year results from the randomized DYNAMIC trial
    Tie, Jeanne
    Wang, Yuxuan
    Lo, Serigne N.
    Lahouel, Kamel
    Cohen, Joshua D.
    Wong, Rachel
    Shapiro, Jeremy David
    Harris, Samuel John
    Khattak, Adnan
    Burge, Matthew E.
    Lee, Margaret
    Harris, Marion
    McLachlan, Sue-Anne
    Ananda, Sumitra
    Underhill, Craig R.
    Papadopoulos, Nickolas
    Tomasetti, Cristian
    Kinzler, Kenneth W.
    Vogelstein, Bert
    Gibbs, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345